Trial · NCT05499052
Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice
NCT05499052, Completed, Ferring Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice. Trials, record NCT05499052. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05499052
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice
- NCT number
- NCT05499052
- Status
- Completed
- Enrollment
- 201 participants, actual
- Lead sponsor
- Ferring Pharmaceuticals
- Conditions
- Controlled Ovarian Stimulation
- Interventions
- REKOVELLE®
- First posted
- 2022-08-12
- Last updated
- 2025-10-02
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Use of the algorithm-based individualized dosing regimen (daily dose of REKOVELLE® administered) | Up to day 1 of REKOVELLE® stimulation | Calculated with body weight and AMH serum level to define the daily dose of REKOVELLE® |
| Primary | Daily dose of REKOVELLE® | From day 1 up to day 20 of REKOVELLE® stimulation | |
| Primary | Number of days of treatment with REKOVELLE® | From day 1 up to day 20 of REKOVELLE® stimulation | |
| Primary | REKOVELLE® Dose changes | From day 1 up to day 20 of REKOVELLE® stimulation | Dose changes is the discretion of the investigator |
| Primary | Use of the Algorithm dosing Application | Up to day 1 of REKOVELLE® stimulation | Use of the Ferring developed dosing app for the daily dose calculation by answering yes/no |
| Primary | Use of GnRH protocol for Lutenizing Hormone surge suppression | Up to day 10 | Defined as a choice between GnRH agonist and GnRH antagonist |
| Primary | Type of drug used for triggering of follicle maturation | Between Day 8 and Day 14 | Defined as a choice between hCG or GnRH |
| Primary | Luteal phase support | 24-72 hours after oocyte-retrieval | Type and the length of luteal phase support is the discretion of the investigator. Decided as a choice between Progesterone, Oestrogen and hCG |
| Secondary | Rate of ongoing pregnancy (≥1 intrauterine viable fetus 10-11 weeks after embryo transfer) in the fresh cycle | 10-11 weeks after embryo transfer | |
| Secondary | Rate of ongoing pregnancy (≥1 intrauterine viable fetus 10-11 weeks after embryo transfer) following the fresh cycle, including also the first frozen embryo transfer | 10-11 weeks after embryo transfer |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40979710 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05499052
GET https://conductscience.org/api/trials/v1/NCT05499052/registered?page=2